Upcoming December 2023 quarterly and activities up till now and general comments
The facts are known and any comments not relating to released information below are my opinion only.
Do your own research.
Cash and equivalents in bank $32 million
Dep Docetaxel mono and combination phase 2 trial completed and data announced.
Dep Cabazitaxel phase 2 trial completed.
Dep Irinotecan mono and combination trial interim data announced and ongoing. This is good because it means there are patients surviving. The longer this happens, the better it is.
As far as licensing deals are concerned……with all 4 drugs Dep Gemcitabine Dep Docetaxel, Dep Irinotecan………multiple discussions with multiple potential licensee’s are ongoing for multiple indications
Radiotheranostics and Antibody Drug Conjugates in house…………ongoing discussions with potential partners to take into the clinic
Genentech, Merck and Chase Sun
How long do we need to go with these research agreements. It must reach a point in time where a line is drawn in the sand, and Starpharma management say time to pay the piper and begin human (as opposed to animal) trials.
Viraleze post market trial completed and data released showing the antiviral nasal spray. We now know from clinical trials that the antiviral can be used as a preventative. It is safe. It reduces viral load in the nose.
Speculation – Bayer would be a good fit for this product. Rumours around……2 years ago there were discussions with them partnering. Maybe Cheryl can revisit this now with such great results from the multiple clinical trials (in the lab, and with humans)
On another note……Allergan would be a good fit for our viral conjunctivitis
Vivagel – I understand the submission to the FDA for an NDA was done in December. It will be confirmed either today or tomorrow
A deal in Europe is pending. Hopefully there will be upfront licensing fees
I look forward to Cheryl updating the market with her thought and strategy in February.
In the meantime, we just need to sit tight and wait
SPL Price at posting:
15.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)